Nanoerythrosomes, a new derivative of erythrocyte ghost: III. Is phagocytosis involved in the mechanism of action?

Anticancer Research

Volumn 17, Issue 5 A, 1997, Pages 3599-3603

  Lejeune, Agnes ^a   Poyet, Patrick ^b   C Gaudreault, Rene ^b   Gicquaud, Claude ^a  

^a UNIVERSITÉ DU QUÉBEC À TROIS RIVIÈRES   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Cancer treatments; Daunorubicin; Drug delivery system; Erythrosome derivatives; Nanoerythrosomes; Phagocytosis; Red blood cell derivatives

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DAUNORUBICIN; DRUG CARRIER;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ERYTHROCYTE GHOST; LEUKEMIA P 388 CELL; MACROPHAGE; MOUSE; NONHUMAN; PHAGOCYTE; PHAGOCYTOSIS; PRIORITY JOURNAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DAUNORUBICIN; DRUG CARRIERS; ERYTHROCYTE MEMBRANE; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; PHAGOCYTOSIS; TUMOR CELLS, CULTURED;

EID: 0030856155     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Leyland-Jones B: Target drug delivery. Seminars in Oncology 20,(1): 12-17, 1993.
2. Gregoriadis G: Engineering liposomes for drug delivery: progress and d problems. TIBTECH 13: 527-537, 1995.
3. Oku N, Namba Y: Long-circulating liposomes. Critical reviews in therapeutic drug carrier systems 11: 231-270, 1994.
4. Tonetti M, De Flora A: Carrier erythrocytes: Clinical pharmacokinetic consideration. Clinical Pharmacokinetic 25: 351-357, 1993
5. C-Gaudreault R, Bellemare B, Lacroix J: Erythrocyte membrane bound daunorubicin as a delivery system in anticancer treatment. Anticancer Res 9: 1201-1206, 1989.
6. Lejeune A, Moorjani M, Gicquaud C, Lacroix J, Poyet P, C-Gaudreault R: Nanoerythrosome, a new derivative of erythrocyte ghost: Preparation and antineoplastic potential as drug carrier for daunorubicin. Anticancer Res 14: 915-920, 1994
7. Moorjani M, Lejeune A, Gicquaud C, Lacroix J, Poyet P, C-Gaudreault R. Nanoerythrosome, a new derivative of erythrocyte ghost II: Identification of the mechanism of action. Anticancer Res 16: 2831-2836, 1996.
8. Fortin A, Shahum E, Krystyniak K, Therien HM: Differential activation of cell-mediated immune functions by encapsulated and surface-linked liposomal antigens. Cellular Immunology 169: 208-217, 1996
9. Colombo R, Milzani A: How does doxorubicin interfere with actin polymerization? Biophys and Biochem Acta 968: 9-16, 1988.
10. Dalledonne I, Milzani A, Colombo R: DXR depresses the α-actinin induced formation of actin bundles. Cancer Biochem Biophys 13: 245-254, 1993
11. Kanbe T, Tsuchiya KS, Hori M, Ekimoto H, Takahashi Y, Takeuchi T: Phenotypic reversion induced by anthracyclines in ras oncogene expressed cells; Structure-Activity Relationships 17: 527-530, 1994.
12. Colin de Verdiere A, Dubernet C, Nemati F, Poupon MF, Puisieux F, Couvreur P: Uptake of doxorubicin from loaded nanoparticles in multidrug-resistant leukemic murine cells. Cancer Chemotherapy Pharmacology 33: 504-508, 1994
13. Henry-Toulme N, Grouselle M, Ramaseilles C: Multidrug resistance by pass in cells exposed to doxorubicin-loaded nanospheres. Biophysical Pharmacology 50: 1135-1139, 1995.
14. Hu Y-P, Jarillon S, Dubernet C, Couvreur P, Robert J: On the mechanism of action of doxorubicin encapsulation in nanosphers for the reversal of multidrug resistance. Cancer Chemotherapy Pharmacology 37: 556-560, 1996.